GSK Partners With Zhifei to Boost Shingles Vaccine Availability in China
09 Outubro 2023 - 3:45AM
Dow Jones News
By Michael Susin
GSK said it has an exclusive agreement with Chongqing Zhifei
Biological Products to co-promote its shingles vaccine Shingrix in
China.
The British pharmaceutical giant on Monday said that Zhifei will
have exclusive rights to import and distribute Shingrix in the
country for an initial three-year period starting from Jan. 1.
The deal will significantly extend the availability of the
vaccine to healthcare professionals and over 30,000 points of
vaccination, it said.
Zhifei is the largest Chinese vaccine company by revenue, GSK
said.
The partnership will also support potential future
co-development and commercialization of GSK's respiratory syncytial
virus vaccine Arexvy in the country.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 09, 2023 02:30 ET (06:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024